[Inhibitors of TNFalpha].
BACKGROUND
TNFalpha inhibitors etanercept and infliximab, are a new and very exciting drugs. Etanercept is administered subcutaneously, and infliximab by intravenous perfusions.


METHODS
They are indicated in severely rheumatoid arthritis resistant to treatment with methotrexate, and in Crohn's disease refractory to immunosuppressive agents. Their safety profile is good, but the risk of infections is increased.


CONCLUSIONS
Their indication in other inflammatory diseases need further studies.
Brousse
C
C
Service de rhumatologie, hôpital Foch, 40, rue Worth, 92150, Suresnes, France. c.brousse@hopital-foch.org <c.brousse@hopital-foch.org>
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D004338:Drug Combinations; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology* / Q000627:therapeutic use; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D004338:Drug Combinations; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept